S'abonner

British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children - 07/08/11

Doi : 10.1016/j.jinf.2009.06.011 
Guy Thwaites a, , h , Martin Fisher b, i , Cheryl Hemingway c, j , Geoff Scott d, k , Tom Solomon e, l , John Innes f, g, m
a Centre for Molecular Microbiology and Infection, Imperial College, Exhibition Road, South Kensington, London, UK 
b Department of HIV/Genitourinary medicine, Brighton and Sussex University Hospitals NHS Trust, Eastern Road, Brighton BN2 5BE, UK 
c Great Ormond Street Hospital for Children, Great Ormond Street, London WC1N 3JH, UK 
d Clinical Microbiology, University College London Hospitals, Windeyer Institute, 46 Cleveland St, London W1T 4 JF, UK 
e Brain Infections Group, Divisions of Neurological Science and Medical Microbiology, University of Liverpool L69 3GA, UK 
f Department of Infection and Tropical Medicine, Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK 
g Department of Respiratory Disease, Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK 

Corresponding author. Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam. Tel.: +84 01273 696955.

Summary and key recommendations

The aim of these guidelines is to describe a practical but evidence-based approach to the diagnosis and treatment of central nervous system tuberculosis in children and adults. We have presented guidance on tuberculous meningitis (TBM), intra-cerebral tuberculoma without meningitis, and tuberculosis affecting the spinal cord. Our key recommendations are as follows: 1. TBM is a medical emergency. Treatment delay is strongly associated with death and empirical anti-tuberculosis therapy should be started promptly in all patients in whom the diagnosis of TBM is suspected. Do not wait for microbiological or molecular diagnostic confirmation. 2. The diagnosis of TBM is best made with lumbar puncture and examination of the cerebrospinal fluid (CSF). Suspect TBM if there is a CSF leucocytosis (predominantly lymphocytes), the CSF protein is raised, and the CSF:plasma glucose is <50%. The diagnostic yield of CSF microscopy and culture for Mycobacterium tuberculosis increases with the volume of CSF submitted; repeat the lumbar puncture if the diagnosis remains uncertain. 3. Imaging is essential for the diagnosis of cerebral tuberculoma and tuberculosis involving the spinal cord, although the radiological appearances do not confirm the diagnosis. A tissue diagnosis (by histopathology and mycobacterial culture) should be attempted whenever possible, either by biopsy of the lesion itself, or through diagnostic sampling from extra-neural sites of disease e.g. lung, gastric fluid, lymph nodes, liver, bone marrow. 4. Treatment for all forms of CNS tuberculosis should consist of 4 drugs (isoniazid, rifampicin, pyrazinamide, ethambutol) for 2 months followed by 2 drugs (isoniazid, rifampicin) for at least 10 months. Adjunctive corticosteroids (either dexamethasone or prednisolone) should be given to all patients with TBM, regardless of disease severity. 5. Children with CNS tuberculosis should ideally be managed by a paediatrician with familiarity and expertise in paediatric tuberculosis or otherwise with input from a paediatric infectious diseases unit. The Children’s HIV Association of UK and Ireland (CHIVA) provide further guidance on the management of HIV-infected children (www.chiva.org.uk). 6. All patients with suspected or proven tuberculosis should be offered testing for HIV infection. The principles of CNS tuberculosis diagnosis and treatment are the same for HIV infected and uninfected individuals, although HIV infection broadens the differential diagnosis and anti-retroviral treatment complicates management. Tuberculosis in HIV infected patients should be managed either within specialist units by physicians with expertise in both HIV and tuberculosis, or in a combined approach between HIV and tuberculosis experts. The co-administration of anti-retroviral and anti-tuberculosis drugs should follow guidance issued by the British HIV association (www.bhiva.org).

Le texte complet de cet article est disponible en PDF.

Keywords : Tuberculosis, Meningitis, Central nervous system, Tuberculoma, Diagnosis, Treatment, Spinal cord, Clinical guidelines


Plan


© 2009  The British Infection Society. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 59 - N° 3

P. 167-187 - septembre 2009 Retour au numéro
Article précédent Article précédent
  • Tuberculous cerebrovascular disease: A review
  • G. Alistair Lammie, Richard H. Hewlett, Johan F. Schoeman, Peter R. Donald
| Article suivant Article suivant
  • Trends in invasive pneumococcal disease among older adults in Olmsted County, Minnesota
  • Constantine Tsigrelis, Imad M. Tleyjeh, Brian D. Lahr, Lisa M. Nyre, Abinash Virk, Larry M. Baddour

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.